menu

Reevaluating Seasonal Influenza in Children and Adults: The Role of Cell-Based Vaccines

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Reevaluating Seasonal Influenza in Children and Adults: The Role of Cell-Based Vaccines

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

An annual flu vaccine is administered to help prevent the flu, but could an alternative method of production impact that vaccine?

  • Sponsored by

  • Overview

    Despite their crucial role in preventing seasonal influenza, traditional influenza vaccines may not be providing as much protection as we thought, leading researchers to take a look at different methods of vaccine production, specifically cell-based flu vaccine production. Here with Dr. Charles Turck to discuss influenza prevention and the latest evidence supporting a cell-based vaccine option is Dr. Mark Blatter.

    USA-QIVc-21-0146 November 2021

  • IMPORTANT SAFETY INFORMATION

    INDICATION AND USAGE
    FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 6 months of age and older.

    CONTRAINDICATIONS
    Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reactions (e.g. anaphylaxis) to any component of the vaccine.

    WARNINGS AND PRECAUTIONS
    If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

    Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

    Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUCELVAX QUADRIVALENT. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope by maintaining a supine or Trendelenburg position.

    After vaccination with FLUCELVAX QUADRIVALENT, immunocompromised individuals, including those receiving immunosuppressive therapy, may have a reduced immune response.

    Vaccination with FLUCELVAX QUADRIVALENT may not protect all vaccine recipients against influenza disease.

    ADVERSE REACTIONS
    In children 6 months through 3 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (27.9%), erythema (25.8%), induration (17.3%) and ecchymosis (10.7%). The most common systemic adverse reactions were irritability (27.9%), sleepiness (26.9%), diarrhea (17.9%) and change of eating habits (17.4%).

    In children 2 through 8 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (28.7%), pain (27.9%) and erythema (21.3%), induration (14.9%) and ecchymosis (10.0%). The most common systemic adverse reactions were sleepiness (14.9%), headache (13.8%), fatigue (13.8%), irritability (13.8%) and loss of appetite (10.6%).

    In children and adolescents 9 through 17 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were injection site pain (21.7%), erythema (17.2%) and induration (10.5%).  The most common systemic adverse reactions were headache (18.1%) and fatigue (17.0%).

    In adults 18 through 64 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were pain (45.4%), erythema (13.4%) and induration (11.6%). The most common systemic adverse reactions were headache (18.7%), fatigue (17.8%) and myalgia (15.4%).

    In adults ≥65 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were pain (21.6%) and erythema (11.9%).

    To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

    Before administration, please see the full US Prescribing Information for FLUCELVAX QUADRIVALENT.

    FLUCELVAX® QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

Schedule29 Jan 2022
Webpack App